HPG 3466
Alternative Names: HPG-3466Latest Information Update: 21 Dec 2021
At a glance
- Originator Hepagene Therapeutics
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hepatitis B
Most Recent Events
- 07 Dec 2021 Preclinical trials in Hepatitis B in China (unspecified route) (Hepagene Therapeutics pipeline, December 2021)